D-0943-2020 Class II Terminated
FDA drug recall D-0943-2020 was initiated by Fusion IV Pharmaceuticals, Inc. Dba Axia Pharmaceutical on Jan 15, 2020 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated Dec 7, 2023).
Recall details
- Product Type
- Drugs
- Report Date
- Mar 11, 2020
- Initiation Date
- Jan 15, 2020
- Termination Date
- Dec 7, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
BETAMETHASONE ACETATE/BETAMETHASONE (PF) Injectable Suspension, Betamethasone Acetate/Betamethasone (PF) CMC [10ML] 7MG/ML INJ SUSP, For IM, IA Use, Shake Well, 10 mL Multi-dose Vial, Rx only, Axia Pharmaceutical 1990 Westwood Blvd. Ste 135, Los Angeles, CA 90025; NDC 71283-0621-1
Reason for recall
Lack of Assurance of Sterility
Distribution pattern
U.S.A. Nationwide and Puerto Rico, Barbados and Dominican Republic
Code information
Lot #: 07092019+52610, Exp 2/6/2020; 07232019+52734, Exp 2/19/2020; 08282019+52853, 09042019+52878, 09102019+52903, Exp 3/2/2020; 09182019+52929, Exp 4/17/2020; 10092019+53082, Exp 2/28/2020, 10152019+53124; Exp 5/4/2020; 10222019+53142, Exp 2/28/2020; 10292019+53160, 11052019+53186, Exp 5/4/2020; 11202019+53257, Exp 6/19/2020; 11212019+53270, Exp 6/20/2020; 12042019+53317, Exp 7/3/2020; 12102019+53363, Exp 7/9/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0943-2020
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026